Aplagon
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutic solutions for severe cardiovascular diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €7.0m | Late VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Developer of antithrombotic compounds designed to treat complications of vascular intervention-related blood vessel occlusions. The company's compounds are engaged in developing biological mimetics of heparin proteoglycan, for the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries, enabling patients to get effective antithrombotic medicines with important safety advantages.
Keywords: Pharmaceuticals and Biotechnology, Antithrombotic Compound, Biotechnology Company, Clinical Management System, Drug Discovery, Drug Discovery Firm, Vascular Disease.